The MEKtrix: Advancing Neurofibromatosis Type 1 Tumor Care Across the Lifespan

Neurofibromatosis Type 1 (NF1) requires a nuanced clinical approach due to its diverse neuro-oncologic manifestations and potential for significant morbidity. To facilitate timely diagnosis and intervention, health care professionals must recognize early neurologic signs and tumor types associated with NF1. The use of mitogen-activated protein kinase inhibitors has emerged as a targeted treatment option for NF1-associated plexiform neurofibromas, in both pediatric and adult populations, necessitating familiarity with their therapeutic role and associated adverse event profiles. Effective management also depends on a coordinated, interprofessional approach that integrates evidence-based strategies and supports individualized, longitudinal care plans tailored to the evolving needs of patients with NF1.

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management.

At the conclusion of this activity, learners will be able to better:

• Assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making
• Evaluate the use of MEK inhibitors in the management of NF1-associated PNs in pediatric and adult patients, including team-based care to manage adverse events
• Develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management

This program is supported through an independent educational grant from SpringWorks Therapeutics, Inc.

Neurologists, neuro-oncologists, neurosurgeons, physician associates (PAs), nurse practitioners (NPs), and nurses

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Brown reports the following financial relationships:

Advisory Board: Alexion Pharmaceuticals, Inc.; Novocure; and Servier

Consultant: Neurovigil, Inc. (unpaid) and Pasithea Therapeutics

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Susan Perry (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.